Skip to main
ELVN

ELVN Stock Forecast & Price Target

ELVN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enliven Therapeutics Inc demonstrates a strong commitment to financial prudence by executing a workforce reduction and reallocating resources to focus on the promising development of HER3-targeting antibody-drug conjugate EO-1022. This strategic pivot aims to enhance the company's potential for revenue generation starting in 2031, as indicated by recent adjustments in their financial model, which prioritize key product candidates. Furthermore, addressing the challenges present in the biotechnology sector reinforces management's proactive approach to managing expenses and optimizing their developmental roadmap, positioning the company favorably for future growth opportunities.

Bears say

Enliven Therapeutics has faced significant setbacks with its development pipeline, notably the decision to discontinue the Claudin 18.2-targeting ADC, EO-3021, due to lower-than-expected efficacy observed in its Phase 1 study, despite the drug's tolerability. The failure to achieve robust efficacy in this candidate raises concerns about the potential for future product development and the company's overall financial health. Furthermore, the downward adjustment of the price target from $6.00 to $1.00 reflects diminished investor confidence in the company’s prospects and future growth potential.

ELVN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enliven Therapeutics Inc (ELVN) Forecast

Analysts have given ELVN a Strong Buy based on their latest research and market trends.

According to 4 analysts, ELVN has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enliven Therapeutics Inc (ELVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.